Ma Huang and the Ephedra Alkaloids

  • Steven B. Karch
Part of the Forensic Science and Medicine book series (FSM)


Ephedra has been used as a natural medicine for thousands of years by numerous cultures with very little concern about toxicity. Its most recent popularity is related to its purported “weight loss” or “performance enhancing” attributes. In spite of that in 2004, concerns over safety resulted in the banning of all over-the-counter (OTC) sales of ephedra-containing dietary supplements by the Food and Drug Administration.

All ephedra plants contain phenylalanine-derived alkaloids, including ephedrine, pseudoephedrine, methylephedrine, and trace amounts of phenylpropanolamine. Previously marketed herbal supplements typically stated total ephedra alkaloid content, although actual levels of individual alkaloid varied depending on raw material and production runs.

A double-blind, placebo-controlled trial by Boozer et al. examined issues of long-term safety and efficacy of ephedra, demonstrating its ability to reduce body weight and body fat while improving blood lipids without significant adverse events. Although other studies have documented a favorable adverse effect profile for appropriately administered doses of ephedra-containing supplements, there have been numerous anecdotal reports of adverse effects. Abuse and misuse of ephedra-containing products likely contributed to spontaneously reported adverse effects and increased concerns over safety.

As with other sympathomimetic agents, theoretical drug interactions with ephedra alkaloids are possible. Despite this potential, only a handful of adverse drug interactions have been reported. This is especially pertinent when considering the extensive use of both ephedra-containing supplements and ephedrineor pseudoephedrine-containing OTC products. The most notable interaction exists between nonselective monoamine oxidase inhibitors and ephedraor ephedrine-containing products.

Key Words

Herbal stimulants weight loss phenylalanine alkaloids bronchodilator athletic performance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lietava J. Medicinal plants in a Middle Paleolithic grave Shanidar IV? J Ethnopharmaco 1992;35(3):263–266.CrossRefGoogle Scholar
  2. 2.
    Kasahara Y, Hikino H, Tsurufuji S, Watanabe M, Ohuchi K. Antiinflammatory actions of ephedrines in acute inflammations. Planta Med 1985;(4):325–331.Google Scholar
  3. 3.
    Grinspoon L, Hedblom P, eds. The speed culture: amphetamine use and abuse in America. Cambridge: Harvard University Press, 1975.Google Scholar
  4. 4.
    al-Khalil S, Alkofahi A, el-Eisawi D, al-Shibib A. Transtorine, a new quinoline alkaloid from Ephedra transitoria. J Nat Prod 1998;61(2):262–263.PubMedCrossRefGoogle Scholar
  5. 5.
    Holmstedt B. Historical perspective and future of ethnopharmacology. J Ethnopharmacol 1991;32(l-3):7–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971; 12:245–248.PubMedGoogle Scholar
  7. 7.
    Deverall RLG. Red China’s dirty drug war; the story of the opium, heroin, morphine and philopon traffic. Tokyo, 1954.Google Scholar
  8. 8.
    Dewick PM, ed. Medicinal natural products: a biosynthetic approach. New York: Wiley, 1997.Google Scholar
  9. 9.
    Yap JC, Critchley LA, Yu SC, Calcroft RM, Derrick JL. A comparison of three fluid-vasopressor regimens used to prevent hypotension during subarachnoid anaesthesia in the elderly. Anaesth Intensive Care 1998;26(5):497–502.PubMedGoogle Scholar
  10. 10.
    Pomerantz B, O’Rourke R. The Stokes-Adams syndrome. Am J Med 1969;46(6):941–960.PubMedCrossRefGoogle Scholar
  11. 11.
    Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes 1998;106(Suppl 2):29–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW. Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. Am J Clin Nutr 1998;68(1):42–51.PubMedGoogle Scholar
  13. 13.
    Greenway F, Herber D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res 1999;7(4):370–378.PubMedGoogle Scholar
  14. 14.
    Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, doubleblind trial. Int J Obes Relat Metab Disord 2001;25(3):316–324.PubMedCrossRefGoogle Scholar
  15. 15.
    Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002;26(5):593–604.PubMedCrossRefGoogle Scholar
  16. 16.
    Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. Sports Med 1997;24(6):366–384.PubMedGoogle Scholar
  17. 17.
    Bell DG, Jacobs I, McLellan TM, Zamecnik J. Reducing the dose of combined caffeine and ephedrine preserves the ergogenic effect. Aviat Space Environ Med 2000;71(4):415–419.PubMedGoogle Scholar
  18. 18.
    Bell DG, Jacobs I, Ellerington K. Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. Med Sci Sports Exerc 2001;33(8): 1399–1403.PubMedCrossRefGoogle Scholar
  19. 19.
    Bell DG, McLellan TM, Sabiston CM. Effect of ingesting caffeine and ephedrine on 10-km run performance. Med Sci Sports Exerc 2002;34(2):344–349.PubMedCrossRefGoogle Scholar
  20. 20.
    Namba T, Kubo M, Kanai Y, Namba K, Nishimura H, Qazilbash NA. Pharmacognostical studies of Ephedra plants Part I — The comparative histological studies on Ephedra rhizomes from Pakistan and Afghanistan and Chinese crude drugs “Ma-Hung-Gen”. Planta Med 1976;29(3):216–225.PubMedGoogle Scholar
  21. 21.
    Sagara K, Oshima T, Misaki T. A simultaneous determination of norephedrine, pseudoephedrine, ephedrine and methylephedrine in Ephedrae Herba and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. Chem Pharm Bull (Tokyo) 1983;31(7):2359–2365.Google Scholar
  22. 22.
    Zhang JS, Tian Z, Lou ZC. [Quality evaluation of twelve species of Chinese Ephedra (ma huang)]. Yao Hsueh Hsueh Pao 1989;24(11):865–871.PubMedGoogle Scholar
  23. 23.
    Anonymous. Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule. Fed Regist 2002;67(60): 14,853–14,862.Google Scholar
  24. 24.
    Gurley BJ, Gardner SF, White LM, Wang PL. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther Drug Monit 1998;20(4):439–445.PubMedCrossRefGoogle Scholar
  25. 25.
    Haller CA, Jacob PIII, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 2002;71(6):421–432.PubMedCrossRefGoogle Scholar
  26. 26.
    Webb AA, Shipton EA. Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section. Can J Anaesth 1998;45(4):367–369.PubMedGoogle Scholar
  27. 27.
    Neve KA, Molinoff PB. Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. Am J Cardiol 1986;57(12):17F–22F.PubMedCrossRefGoogle Scholar
  28. 28.
    Williams BR, Barber R, Clark RB. Kinetic analysis of agonist-induced down regulation of the beta(2)-adrenergic receptor in BEAS-2B cells reveals high-and low-affinity components. Mol Pharmacol 2000;58(2):421–430.PubMedGoogle Scholar
  29. 29.
    Saupe KW, Smith CA, Henderson KS, Dempsey JA. Diastolic time: an important determinant of regional arterial blood flow. Am J Physiol 1995;269(3 Pt 2):H973–H979.PubMedGoogle Scholar
  30. 30.
    Muittari A, Mattila MJ, Tiitinen H. The combined action of broncholytic agents in asthmatic patients: orciprenaline, isoprenaline, and ephedrine. Ann Med Intern Fenn 1968;57(l):31–35.PubMedGoogle Scholar
  31. 31.
    Muittari A, Mattila MJ, Patiala J. Bronchodilator action of drug combinations in asthmatic patients: decloxizine, orciprenaline, and ephedrine. Ann Allergy 1969;27(6):274–279.PubMedGoogle Scholar
  32. 32.
    Muittari A, Mattila MJ. Bronchodilator action of drug combinations in asthmatic patients. Ephedrine, theophylline and tranquilizing drugs. Curr Ther Res Clin Exp 1971;13(6):374–385.PubMedGoogle Scholar
  33. 33.
    Dulfano MJ, Glass P. Evaluation of a new B 2 adrenergic receptor stimulant, terbutaline, in bronchial asthma. II. Oral comparison with ephedrine. Curr Ther Res Clin Exp 1973; 15(4): 150–157.PubMedGoogle Scholar
  34. 34.
    Kerr A, Gebbie T. Comparison of orciprenaline, ephedrine and methoxyphenamine as oral bronchodilators. N Z Med J 1973;77(492):320–322.PubMedGoogle Scholar
  35. 35.
    Weinberger MM, Bronsky EA. Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children. J Pediatr 1974;84(3):421–427.PubMedCrossRefGoogle Scholar
  36. 36.
    Bierman CW, Pierson WE, Shapiro GG. Exercise-induced asthma. Pharmacological assessment of single drugs and drug combinations. JAMA 1975;234(3):295–298.PubMedCrossRefGoogle Scholar
  37. 37.
    Bierman CW, Pierson WE, Shapiro GG. The pharmacological assessment of single drugs and drug combinations in exercise-induced asthma. Pediatrics 1975;56(5 Pt-2 Suppl):919–922.PubMedGoogle Scholar
  38. 38.
    Bye C, Hill HM, Hughes DT, Peck AW. A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. Eur J Clin Pharmacol 1975;8(l):47–53.PubMedCrossRefGoogle Scholar
  39. 39.
    Chervinsky P, Chervinsky G. Metaproterenol tablets: their duration of effect by comparison with ephedrine. Curr Ther Res Clin Exp 1975;17(6):507–518.PubMedGoogle Scholar
  40. 40.
    Geumei A, Miller WF, Paez PN, Gast LR. Evaluation of a new oral beta2 adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology 1975;13(3):201–211.PubMedCrossRefGoogle Scholar
  41. 41.
    Nelson HS, Black JW, Branch LB, et al. Subsensitivity to epinephrine following the administration of epinephrine and ephedrine to normal individuals. J Allergy Clin Immunol 1975;55(5):299–309.PubMedCrossRefGoogle Scholar
  42. 42.
    Tashkin DP, Meth R, Simmons DH, Lee YE. Double-blind comparison of acute bronchial and cardiovascular effects of oral terbutaline and ephedrine. Chest 1975;68(2): 155–161.PubMedGoogle Scholar
  43. 43.
    Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ. Interaction of ephedrine and theophylline. Clin Pharmacol Ther 1975;17(5):585–592.PubMedGoogle Scholar
  44. 44.
    Blumberg MZ, Tinkelman DG, Ginchansky EJ, Blumberg BS, Taylor JC, Avner SE. Terbutaline and ephedrine in asthmatic children. Pediatrics 1977;60(l):14–19.PubMedGoogle Scholar
  45. 45.
    Simi WW, Miller WC. Clinical investigation of fenoterol, a new bronchodilator, in asthma. J Allergy Clin Immunol 1977;59(2):178–181.PubMedCrossRefGoogle Scholar
  46. 46.
    Tinkelman DG, Avner SE. Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects. JAMA 1977;237(6):553–557.PubMedCrossRefGoogle Scholar
  47. 47.
    Tinkelman DG, Avner SE. Assessing bronchodilator responsiveness. J Allergy Clin Immunol 1977;59(2): 109–114.PubMedCrossRefGoogle Scholar
  48. 48.
    Bush RK, Smith AM, Welling PG, Alcala JC, Lee TP. A comparison of atheophylline-ephedrine combination with terbutaline. 1 1978;41(1): 13–17.Google Scholar
  49. 49.
    Chervinsky P. The development of drug tolerance during long-term beta2 agonist bronchodilator therapy. Chest 1978;73(6 Suppl): 1001–1002.PubMedGoogle Scholar
  50. 50.
    Cohen BM. The cardiorespiratory effects of oral terbutaline and an ephedrinetheophylline-phenobarbital combination: comparison in patients with chronic obstructive ventilatory disorders. Ann Allergy 1978;40(4):233–239.PubMedGoogle Scholar
  51. 51.
    Eggleston PA, and McMahan S. A. The effects of fenoterol, ephedrine and placebo on exercise-induced asthma. Chest 1978;73(6 Suppl): 1006–1008.PubMedGoogle Scholar
  52. 52.
    Falliers CJ. Controlled assessment of beta2 adrenergic therapy for childhood asthma. Chest 1978;73(6 Suppl): 1008–1010.PubMedGoogle Scholar
  53. 53.
    Falliers CJ, Cato AE, Harris JR. Controlled assessment of oral bronchodilators for asthmatic children. J Int Med Res 1978;6(4):326–336.PubMedGoogle Scholar
  54. 54.
    Miller WC. Long-term beta2 bronchodilator therapy and the question of tolerance. Chest 1978;73(6 Suppl): 1000–1001.PubMedGoogle Scholar
  55. 55.
    Stenius B, Haahtela T, Poppius H. Controlled comparison of Nuelin, Theodrox and Marax in asthmatic out-patients. Eur J Clin Pharmacol 1978;13(3): 179–183.PubMedCrossRefGoogle Scholar
  56. 56.
    VanArsdel PPJr, Schaffrin RM, Rosenblatt J, Sprenkle AC, Altaian LC. Evaluation of oral fenoterol in chronic asthmatic patients. Chest 1978;73(6 Suppl):997–998.PubMedGoogle Scholar
  57. 57.
    Banner AS, Sunderrajan EV, Agarwal MK, Addington WW. Arrhythmogenic effects of orally administered bronchodilators. Arch Intern Med 1979;139(4):434–437.PubMedCrossRefGoogle Scholar
  58. 58.
    James TD, Lyons HA. A comparative study of bronchodilator effects of carbuterol and ephedrine. JAMA 1979;241(7):704–705.PubMedCrossRefGoogle Scholar
  59. 59.
    Muittari A, Mattila MJ. Objective and subjective assessment of ephedrine combinations in asthmatic outpatients. Ann Clin Res 1979;11(3):87–89.PubMedGoogle Scholar
  60. 60.
    Pierson DJ, Hudson LD, Stark K, Hedgecock M. Cardiopulmonary effects of terbutaline and a bronchodilator combination in chronic obstructive pulmonary disease. Chest 1980;77(2): 176–182.PubMedGoogle Scholar
  61. 61.
    Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 1999;58(5):807–810.PubMedCrossRefGoogle Scholar
  62. 62.
    Astrup A. Thermogenic drugs as a strategy for treatment of obesity. Endocrine 2000;13(2):207–212.PubMedCrossRefGoogle Scholar
  63. 63.
    Bray GA. Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S8–S17.PubMedGoogle Scholar
  64. 64.
    Cheng JT, Liu IM, Yen ST, Juang SW, Liu TP, Chan P. Stimulatory effect of Dephedrine on beta3 adrenoceptors in adipose tissue of rats. Auton Neurosci 2001;88(l-2):1–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Castleden CM, Duffin HM, Briggs RS, Ogden BM. Clinical and urodynamic effects of ephedrine in elderly incontinent patients. J Urol 1982; 128(6): 1250–1252.PubMedGoogle Scholar
  66. 66.
    Kadar N, Nelson JHJr. Treatment of urinary incontinence after radical hysterectomy. Obstet Gynecol 1984;64(3):400–405.PubMedGoogle Scholar
  67. 67.
    Alberts P, Bergstrom PA, Fredrickson MG. Characterisation of the functional alpha-adrenoceptor subtype in the isolated female pig urethra. Eur J Pharmacol 1999;371(l):31–38.PubMedCrossRefGoogle Scholar
  68. 68.
    Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord 1992;16(4):269–277.PubMedGoogle Scholar
  69. 69.
    Kanfer IR, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993;13(6-2):116S–128S; discussion 143S-146S.PubMedGoogle Scholar
  70. 70.
    White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardiovascular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol 1997;37(2): 116–122.PubMedGoogle Scholar
  71. 71.
    Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. Clin Pharmacol Ther 1971;12(1):62–67.PubMedGoogle Scholar
  72. 72.
    Dickerson J, Perrier D, Mayersohn M, Bressler R. Dose tolerance and pharmacokinetic studies of L(+) pseudoephedrine capsules in man. Eur J Clin Pharmacol 1978; 14:239–259.CrossRefGoogle Scholar
  73. 73.
    Vanakoski J, Seppala T. Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics. Clin Pharmacokinet 1998;34(4):311–322.PubMedCrossRefGoogle Scholar
  74. 74.
    Wilkinson G, Beckett A. Absorption, metabolism and excretion of the ephedrine in man. II. 1 1968;57:1933–1938.Google Scholar
  75. 75.
    Kunsman GW, Jones R, Levine B, Smith ML. Methylephedrine concentrations in blood and urine specimens. J Anal Toxicol 1998;22(4):310–313.PubMedGoogle Scholar
  76. 76.
    Tokunaga I, Takeichi S, Kujime T, Maeiwa M. Electroencephalographical analysis of acute drug intoxication — SS Bron solution-W. Arukoru Kenkyuto Yakubutsu Ison 1989;24(6):471–479.PubMedGoogle Scholar
  77. 77.
    Ishigooka J, Yoshida Y, Murasaki M. Abuse of “BRON”: a Japanese OTC cough suppressant solution containing methylephedrine, codeine, caffeine and chlorpheniramine. Prog Neuropsychopharmacol Biol Psychiatry 1991;15(4):513–521.PubMedCrossRefGoogle Scholar
  78. 78.
    Levine B, Caplan YH, Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986;10(5):209–210.PubMedGoogle Scholar
  79. 79.
    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343(25): 1833–1838.PubMedCrossRefGoogle Scholar
  80. 79a.
    Haller CA and Benowitz NL. Dietary supplements containing ephedra alkaloids, correspondence. N Engl J Med 2000;344(April 5): 1095–1097.Google Scholar
  81. 80.
    Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77(l): 12–16.PubMedCrossRefGoogle Scholar
  82. 81.
    Kingston R, Blumenthal M. A rational perspective on adverse events reports on herbs: misinterpretation of adverse reactions tabulated in the TESS Annual Report of the American Association of Poison Control Centers as they relate to ephedra dietary supplements. HerbalGram 2003;60:48–53.Google Scholar
  83. 82.
    Pentel P. Toxicity of over-the-counter stimulants. JAMA 1984;252(14): 1898–1903.PubMedCrossRefGoogle Scholar
  84. 83.
    Stoessl AJ, Young GB, Feasby TE. Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. Stroke 1985;16(4):734–736.PubMedGoogle Scholar
  85. 84.
    Roberge RJ, Hirani KH, Rowland PLIII, Berkeley R, Krenzelok EP. Dextromethorphan-and pseudoephedrine-induced agitated psychosis and ataxia: case report. J Emerg Med 1999;17(2):285–288.PubMedCrossRefGoogle Scholar
  86. 85.
    Wilson H, Woods D. Pseudoephedrine causing mania-like symptoms. N Z Med J 2002;115(1148):86.PubMedGoogle Scholar
  87. 86.
    Johnson DA, Etter HS, Reeves DM. Stroke and phenylpropanolamine use. Lancet 1983;2(8356):970.PubMedCrossRefGoogle Scholar
  88. 87.
    Glick R, Hoying J, Cerullo L, Perlman S. Phenylpropanolamine: an over-thecounter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. Neurosurgery 1987;20(6):969–974.Google Scholar
  89. 88.
    Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebocontrolled follow-up study. Am J Med 1989;86(4):427–432.PubMedCrossRefGoogle Scholar
  90. 89.
    Thomas SH, Clark KL, Allen R, Smith SE. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. Br J Clin Pharmacol 1991;32(6):705–711.PubMedGoogle Scholar
  91. 90.
    Ryu SJ, Lin SK. Cerebral arteritis associated with oral use of phenylpropanolamine: report of a case. J Formos Med Assoc 1995;94(l-2):53–55.PubMedGoogle Scholar
  92. 91.
    Tapia J. [Cerebral hemorrhage associated with the use of phenylpropanolamine. Clinical cases]. Rev Med Chil 1996;124(12):1499–1503.PubMedGoogle Scholar
  93. 92.
    Chung YT, Hung DZ, Hsu CP, Yang DY, Wu TC. Intracerebral hemorrhage in a young woman with arteriovenous malformation after taking diet control pills containing phenylpropanolamine: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61(7):432–435.Google Scholar
  94. 93.
    Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25): 1826–1832.PubMedCrossRefGoogle Scholar
  95. 94.
    Vahedi K, Domigo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. J Neurol Neurosurg Psychiatry 2000;68(l): 112–113.PubMedCrossRefGoogle Scholar
  96. 95.
    du Boisgueheneuc F, Lannuzel A, Caparros-Lefebvre D, De Broucker T. [Cerebral infarction in a patient consuming MaHuang extract and guarana]. Presse Med 2001;30(4):166–167.PubMedGoogle Scholar
  97. 96.
    Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. Neurology 1993;43(7):1313–1316.PubMedGoogle Scholar
  98. 97.
    Loizou LA, Hamilton JG, Tsementzis SA. Intracranial haemorrhage in association with pseudoephedrine overdose. J Neurol Neurosurg Psychiatry 1982;45(5):471–472.PubMedGoogle Scholar
  99. 98.
    LeBayon A, Castelnovo G, Briere C, Labauge P. [Cerebromeningeal hemorrhage after voluntary overdose of pseudoephedrine]. Presse Med 2000;29(31):1702.PubMedGoogle Scholar
  100. 99.
    Mourand I, Ducrocq X, Lacour JC, Taillandier L, Anxionnat R, Weber M. Acute reversible cerebral arteritis associated with parenteral ephedrine use. Cerebrovasc Dis 1999;9(6):355–357.PubMedCrossRefGoogle Scholar
  101. 100.
    Jovanovic Z. [Risk factors for stroke in young people]. Srp Arh Celok Lek 1996;124(9–10):232–235.PubMedGoogle Scholar
  102. 101.
    Herridge CF, a’Brook MF. Ephedrine psychosis. Br Med J 1968;2(598):160.PubMedGoogle Scholar
  103. 102.
    Roxanas MG, Spalding J. Ephedrine abuse psychosis. Med J Aust 1977;2(19):639–640.PubMedGoogle Scholar
  104. 103.
    Shufman NE, Witztum E, Vass A. [Ephedrine psychosis]. Harefuah 1994;127(5–6):166–168, 215.PubMedGoogle Scholar
  105. 104.
    Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. BMJ 1996;313(7059):756.PubMedGoogle Scholar
  106. 105.
    Tormey WP, Bruzzi A. Acute psychosis due to the interaction of legal compounds — ephedra alkaloids in “vigueur fit” tablets, caffeine in “red bull” and alcohol. Med Sci Law 2001;41(4):331–336.PubMedGoogle Scholar
  107. 106.
    Kalix P. The pharmacology of psychoactive alkaloids from ephedra and catha. J Ethnopharmacol 1991;32(l–3):201–208.PubMedCrossRefGoogle Scholar
  108. 107.
    Bories H. [Kidney stones]. Infirm Fr 1976;(179): 13–18.Google Scholar
  109. 108.
    Schweisheimer W. [Kidneystones]. Krankenpflege (Frankf) 1976;30(6): 194–195.Google Scholar
  110. 109.
    Blau JJ. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol 1998;160(3–1):825.PubMedGoogle Scholar
  111. 110.
    Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 1998;32(1): 153–159.PubMedGoogle Scholar
  112. 111.
    Assimos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. Guaifenesin-and ephedrine-induced stones. J Endourol 1999;13(9):665–667.PubMedGoogle Scholar
  113. 112.
    Glidden RS, DiBona FJ. Urinary retention associated with ephedrine. J Pediatr 1977;90(6):1013–1014.PubMedCrossRefGoogle Scholar
  114. 113.
    Lindberg AW. [Urinary retention caused by Elsinore pills]. Ugeskr Laeger 1988;150(35):2086–2087.PubMedGoogle Scholar
  115. 114.
    Lyon CC, Turney JH. Pseudoephedrine toxicity in renal failure. Br J Clin Pract 1996;50(7):396–397.PubMedGoogle Scholar
  116. 115.
    Brater DC, Kaojarern S, Benet LZ, et al. Renal excretion of pseudoephedrine. Clin Pharmacol Ther 1980;28(5):690–694.PubMedCrossRefGoogle Scholar
  117. 116.
    Karch SB, Stephens B, Ho CH. Relating cocaine blood concentrations to toxicity — an autopsy study of 99 cases. J Forensic Sci 1998;43(1):41–45.PubMedGoogle Scholar
  118. 117.
    Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 1999;44(2):359–368.PubMedGoogle Scholar
  119. 118.
    To LB, Sangster JF, Rampling D, Cammens I. Ephedrine-induced cardiomyopathy. Med J Aust 1980;2(l):35–36.PubMedGoogle Scholar
  120. 119.
    Gaultieri J. Cardiomyopathy in a heavy ephedrine abuser. J Tox Clin Tox 1996;34:581–582.Google Scholar
  121. 120.
    Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. Med J Aust 1997; 167(4): 199–200.PubMedGoogle Scholar
  122. 121.
    Menegakis NE, Amstey MS. Case report of myocardial infarction in labor. Am J Obstet Gynecol 1991;165(5-1):1383–1384.PubMedGoogle Scholar
  123. 122.
    Wiener I, Tilkian AG, Palazzolo M. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. Cathet Cardiovasc Diagn 1990;20(l):51–53.PubMedCrossRefGoogle Scholar
  124. 123.
    Derreza H, Fine MD, Sadaniantz A. Acute myocardial infarction after use of pseudoephedrine for sinus congestion. J Am Board Fam Pract 1997;10(6):436–438.PubMedGoogle Scholar
  125. 124.
    Hirabayashi Y, Saitoh K, Fukuda H, Mitsuhata H, Shimizu R. Coronary artery spasm after ephedrine in a patient with high spinal anesthesia. Anesthesiology 1996;84(l):221–224.PubMedCrossRefGoogle Scholar
  126. 125.
    Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999;37(4):485–489.PubMedCrossRefGoogle Scholar
  127. 126.
    Anastasio GD, Harston PR. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. J Am Board Fam Pract 1992;5(5):527–528.PubMedGoogle Scholar
  128. 127.
    Onuigbo M, Alikhan M. Over-the-counter sympathomimetics: a risk factor for cardiac arrhythmias in pregnancy. South Med J 1998;91(12): 1153–1155.PubMedGoogle Scholar
  129. 128.
    Weesner KM, Denison M, Roberts RJ. Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. Clin Pediatr (Phila) 1982;21(11):700–701.CrossRefGoogle Scholar
  130. 129.
    Hanzlick R, Davis G. National Association of Medical Examiners Pediatric Toxicology Registry. Report 1: Phenylpropanolamine. Am J Forensic Med Pathol 1992;13(1):37–41.PubMedCrossRefGoogle Scholar
  131. 130.
    Levisky JA, Karch SB, Bowerman DL, Jenkins WW, Johnson DG, Davies D. False-positive RIA for methamphetamine following ingestion of an ephedra-derived herbal product. J Anal Toxicol 2003;27:123–124.PubMedGoogle Scholar
  132. 131.
    Backer R, Tautman D, Lowry S, Harvey CM, Poklis A. Fatal ephedrine intoxication. J Forensic Sci 1997;42(1): 157–159.PubMedGoogle Scholar
  133. 132.
    Levine B, Jones R, Klette K, Smith ML, Kilbane E. An intoxication involving BRON and verapamil. J Anal Toxicol 1993;17(6):381–383.PubMedGoogle Scholar
  134. 133.
    Baselt RC, Cravey RH, eds. Disposition of toxic drugs and chemicals in man. Foster City: Chemical Toxicology Institute, 1995.Google Scholar
  135. 134.
    Hedetoft C, Jensen CH, Christensen MR, Christensen O. [Fatal poisoning with Letigen]. Ugeskr Laeger 1999;161(50):6937–6938.PubMedGoogle Scholar
  136. 135.
    Blechman KM, Karch SB, Stephens BG. Demographic, pathologic, and toxicological profiles of 127 decedents testing positive for ephedrine alkaloids. Forensic Sci Int. 2004;139(l):61–69 as n.PubMedCrossRefGoogle Scholar
  137. 136.
    Irvine G, Chen L, eds. The environmental impact and adverse health effects of clandestine manufacture of methamphetamine. NID A Research Monograph 115. Miller MA, Kozel NJ, eds. N. Bethesda: National Institute on Drug Abuse, 1991, pp.33–46.Google Scholar
  138. 137.
    Dingemanse J, Guentert T, Gieschke R, Stabl M. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide. J Cardiovasc Pharmacol 1996;28(6):856–861.PubMedCrossRefGoogle Scholar
  139. 138.
    Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol (Oxf) 1995;42(l):95–98; discussion 98-99.Google Scholar
  140. 139.
    Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med 1995; 12(1):49–51.PubMedGoogle Scholar
  141. 140.
    Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1994;12(6):642–644.PubMedCrossRefGoogle Scholar
  142. 141.
    Reeves RR, Pinkofsky HB. Postpartum psychosis induced by bromocriptine and pseudoephedrine. J Fam Pract 1997;45(2):164–166.PubMedGoogle Scholar
  143. 142.
    Inomata S, Nishikawa T, Kihara S, Akiyoshi Y. Enhancement of pressor response to intravenous phenylephrine following oral clonidine medication in awake and anaesthetized patients. Can J Anaesth 1995;42(2):119–125.PubMedGoogle Scholar
  144. 143.
    Tanaka M, Nishikawa T. Enhancement of pressor response to ephedrine following clonidine medication. Anaesthesia 1996;51(2):123–127.PubMedCrossRefGoogle Scholar
  145. 144.
    Tekol Y, Tercan E, Esmaoglu A. Ephedrine enhances analgesic effect of morphine. Acta Anaesthesiol Scand 1994;38(4):396–397.PubMedGoogle Scholar
  146. 145.
    Walton R, Manos GH. Psychosis related to ephedra-containing herbal supplement use. South Med J 2003;96:718–720.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Steven B. Karch

There are no affiliations available

Personalised recommendations